Work

Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer

Year: 2021

Type: article

Source: Gynecologic Oncology

DOI: 10.1016/j.ygyno.2021.04.015

Authors: Vijayalaxmi G. Gupta, Jeff Hirst, Shariska Petersen, Katherine F. Roby, Meghan Kusch, Helen Zhou, Makena L. Clive, Andrea Jewell, Harsh B. Pathak, Andrew K. Godwin, Andrew J. Wilson, Marta A. Crispens, Emily Cybulla, Alessandro Vindigni, Katherine C. Fuh, Dineo Khabele

Institutions: Washington University in St. Louis, University of Kansas Medical Center, The University of Kansas Cancer Center, Vanderbilt University, Vanderbilt University Medical Center, Saint Louis University

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: National Institutes of Health, National Cancer Institute, National Institute of General Medical Sciences

Awards: G1626077443, G2954940344, G4525661843, G664674768, G700021213, The Kansas Institute for Precision Medicine, The University of Kansas Cancer Center

OpenAlex ID: W3152687170

FWCI: 2.035

Cites: 65

Cited by: 39

Related to: 10